|
Oct 9
|
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
|
|
Sep 5
|
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Sep 3
|
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
|
|
Jun 25
|
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
|
|
Jun 21
|
When Can We Expect A Profit From Unicycive Therapeutics, Inc. (NASDAQ:UNCY)?
|
|
Nov 29
|
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
|
|
Sep 6
|
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
|
|
Jul 18
|
Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
|
|
Mar 8
|
We're A Little Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
|
|
Mar 7
|
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
|
|
Mar 6
|
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
|